WCN26-8804 The Novel Sorbent ZO is an Effective Oral Gut Phosphate Binder: Therapeutic Implications for the CKD- and ESRD-associated Hyperphosphatemia

Read full text Summarise with VIRAT
Authors: Khalid A. Abdelhalim, Yanzhe Wang, Asadoor Amirkhani Namagerdi, Narjes Alfuraiji, David Mburu, Karoona Bai, Bilal Ali, Nusiba Elsanousi, David John Carr, Stephen R. Ash, Hatim A. Hassan
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Hyperphosphatemia due to declining kidney function is linked to disease progression and increased cardiovascular morbidity and mortality. Despite current oral phosphate binders, many patients with chronic kidney disease (CKD) and end stage kidney disease (ESKD) fail to maintain target serum phosphate concentrations, with poor adherence to these binders due to the high pill burden required to effectively capture dietary phosphate as a key contributing factor. Importantly, up to 50% of patients on dialysis and phosphate binders still have abnormally high serum phosphate.

Fields of Study & Subjects

Parathyroid Disorders and Treatments Dialysis and Renal Disease Management Potassium and Related Disorders

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104281–104281
Publication date
25 March 2026
Language
EN